SH3PXD2A and prostate cancer: High expression of Tks5 has previously been reported in some cancer types, such as glial-derived brain tumors [38], lung adenocarcinomas [39], prostate cancer [40] and breast cancer [21], and can correlate with poorer outcome [21, 38, 39].